The Right Play On BioMarin Pharmaceuticals

BioMarin Pharmaceuticals recently announced it is acquiring Amicus Therapeutics for $4.8B, adding two rare disease assets with blockbuster potential and strategic synergies. The acquisition provides insurance against competitive threats to Voxzogo, BMRN's key growth driver facing pressure from Ascendis and BridgeBio pipeline advances. The deal is initially slightly dilutive to 2026 non-GAAP EPS but is expected to be substantially accretive from 2027 as synergies and expansion opportunities materialize.

Seeking Alpha • Feb 1, 2026

Should You Buy BioMarin Pharmaceutical Before Feb. 18?

BioMarin expects strong sales for its rare-disease drug, Voxzogo, in Q4. The company also has several important catalysts on the way in the first half of the year.

The Motley Fool • Jan 31, 2026

BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes").

PRNewsWire • Jan 29, 2026

BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

SAN RAFAEL, Calif., Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the "Notes").

PRNewsWire • Jan 26, 2026

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jan 16, 2026

Buy These 5 Price-to-Book Value Stocks for Gains in 2026

Five low price-to-book stocks stand out for 2026, as undervalued valuations and solid growth outlooks put them on investors' radar.

Zacks Investment Research • Jan 15, 2026

4 Value Stocks to Buy As Wall Street Weighs Trump Policies

As markets reel from policy uncertainty, UHS, PNC, GPN, and BMRN emerge as compelling value picks with strong cash flow.

Zacks Investment Research • Jan 14, 2026

Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Jan 13, 2026

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jan 13, 2026

BMRN or TARS: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Tarsus Pharmaceuticals, Inc. (TARS). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 13, 2026